Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
TG Therapeutics
TGTX
TG Therapeutics
Aging Populations And Self-Administration Will Transform MS Care
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
01 May 25
Updated
20 Aug 25
1
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$53.00
44.4% undervalued
intrinsic discount
20 Aug
US$29.45
Loading
1Y
20.4%
7D
4.9%
Author's Valuation
US$53.0
44.4% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
1
Shared on
07 May 25
Read more
0
votes
Share
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$53.0
44.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-343m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.5b
Earnings US$641.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
26.40%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$641.62m
Earnings '28
x
15.39x
PE Ratio '28
=
US$9.87b
Market Cap '28
US$9.87b
Market Cap '28
/
153.26m
No. shares '28
=
US$64.41
Share Price '28
US$64.41
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$52.91
Fair Value '25